QNCX logo

QUINCE THERAPEUTICS INC

QNCXNASDAQ
🏆 #5054 by market capUS Equity
$30.19▲ $1.48 (+4.90%)
After hours · at close
🔔
Track QNCX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.9%
7d▼ 8.5%
14d▲ 7.8%
30d▼ 10.0%
ytd▼ 95.5%
1y▼ 90.7%
🏦Market Cap
$8M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
72
Fair

Trading Snapshot

Day Range
$29.72 – $30.50
52-Week Range
$15.10 – $910.00
Volume
$3.39B
Avg Volume
$2.42B
Shares Outstanding
278,408
Next Earnings
Oct 31, 2026

Fundamentals Snapshot

Annual Revenue
$955,129
Last Q Revenue
$248,619
P/E Ratio
-0.4
P/S Ratio
0.0x
EPS (TTM)
$-15.08
Dividend Yield
0.00%
Dilution (1yr)
+15.8%

Why Investors Own QNCX

  • ✓High-growth profile — revenue up +53.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 63% gross margin and 13% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

QNCX logo

QUINCE THERAPEUTICS INC

QNCX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$50M▼ −12.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$42M▲ +29.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
250K▲ +15.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$13M▼ −$4M YoY
StockOtter · stockotter.space

About QUINCE THERAPEUTICS INC

Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$32.71
▲ +8.3% Upside
High Target$37.80
Low Target$29.93
Based on 37 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

QUINCE THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift QNCX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

QUINCE THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.